Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. director Arthur A. Torres reported selling a total of 10,570 shares of common stock in open-market transactions over two days. He sold 4,086 shares on May 14, 2026 at a weighted average price of $20.9735 per share, in trades ranging from $20.96 to $21.03. He then sold 6,484 shares on May 15, 2026 at a weighted average price of $19.8917 per share, in trades ranging from $19.73 to $20.105. After these sales, Torres directly holds 38,665 shares of CareDx common stock.
CDNA insider filing: Arthur Torres reported a Rule 144 notice related to restricted Common stock and recent sales. The filing lists 6,484 restricted Common shares noted under "Securities To Be Sold" with an effective date of 06/14/2025. It also reports 4,086 Common shares sold on 05/14/2026 for $85,697.72.
CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, executed an open-market sale of 2,688 shares of common stock on May 5, 2026 at a weighted average price of 20.6775 per share. After the sale, he directly owned 113,924 shares of CareDx common stock. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan, which had been adopted on September 4, 2025, and the sale prices ranged from 20.405 to 21.26 per share.
CareDx, Inc. reported a routine insider tax-related transaction by its Secretary and General Counsel, Jeffrey Adam Novack. On May 1, 2026, 2,873 shares of common stock were withheld by the company at $21.50 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Novack directly held 116,612 shares of CareDx common stock. This was a compensation-related tax-withholding event, not an open-market purchase or sale.
CareDx, Inc. filed an automatic shelf registration on Form S-3 to register an unspecified aggregate amount of common stock, preferred stock, debt securities, warrants, subscription rights and/or units from time to time after this registration statement becomes effective. The shelf prospectus describes broad terms and distribution methods and states that each offering will be detailed in a prospectus supplement.
The prospectus notes 51,274,651 shares of common stock outstanding as of March 31, 2026, authorized capital of 100,000,000 common shares and 10,000,000 preferred shares, and discloses outstanding equity awards and the Nasdaq listing (symbol CDNA).
CareDx, Inc. filed an automatic shelf registration on Form S-3 to register an unspecified aggregate amount of common stock, preferred stock, debt securities, warrants, subscription rights and/or units from time to time after this registration statement becomes effective. The shelf prospectus describes broad terms and distribution methods and states that each offering will be detailed in a prospectus supplement.
The prospectus notes 51,274,651 shares of common stock outstanding as of March 31, 2026, authorized capital of 100,000,000 common shares and 10,000,000 preferred shares, and discloses outstanding equity awards and the Nasdaq listing (symbol CDNA).
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. entered into a definitive agreement to acquire Naveris, Inc., expanding from transplant diagnostics into viral‑mediated cancer MRD surveillance. The deal includes $160 million in upfront cash plus up to $100 million in revenue‑based milestone payments. Naveris generated unaudited $34 million revenue in 2025 and about $12 million in first‑quarter 2026, and CareDx expects the transaction to be neutral to its 2026 adjusted EBITDA guidance.
CareDx reported strong first‑quarter 2026 results with total revenue of $117.7 million, up 39% from a year earlier, and GAAP net income of $2.8 million versus a prior‑year loss. Non‑GAAP net income was $18.1 million, and adjusted EBITDA rose to $18.9 million. The company raised full‑year 2026 revenue guidance to $447–$465 million and adjusted EBITDA guidance to $43–$57 million.
The Board also authorized a new common stock repurchase program of up to $100 million over 24 months starting April 30, 2026, to be funded from existing cash and future cash flow, in addition to a prior $50 million program.
CareDx, Inc. entered into a definitive agreement to acquire Naveris, Inc., expanding from transplant diagnostics into viral‑mediated cancer MRD surveillance. The deal includes $160 million in upfront cash plus up to $100 million in revenue‑based milestone payments. Naveris generated unaudited $34 million revenue in 2025 and about $12 million in first‑quarter 2026, and CareDx expects the transaction to be neutral to its 2026 adjusted EBITDA guidance.
CareDx reported strong first‑quarter 2026 results with total revenue of $117.7 million, up 39% from a year earlier, and GAAP net income of $2.8 million versus a prior‑year loss. Non‑GAAP net income was $18.1 million, and adjusted EBITDA rose to $18.9 million. The company raised full‑year 2026 revenue guidance to $447–$465 million and adjusted EBITDA guidance to $43–$57 million.
The Board also authorized a new common stock repurchase program of up to $100 million over 24 months starting April 30, 2026, to be funded from existing cash and future cash flow, in addition to a prior $50 million program.